Docetaxel in Advanced Gastric Cancer
Review of the Main Clinical Trials

References

• Jemal A, Murray T, Samuels A, et al. Cancer statistics, 2003. CA Cancer J Clin 2003; 53: 5–26.
   PubMed Web of Science ®Google Scholar
• Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin 1999; 49: 8.
   PubMed Web of Science ®Google Scholar
• Karpeh MS, Kelsen DP, Tepper JE. Cancer of the stomach. In: De Vita VT, Hellman S, Rosenberg SA. 'Cancer. Priciples and practice of oncology, 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2001. p. 1092.
   Google Scholar
• Pazdur R, Kudelka AP, Kavanagh JJ, et al. The taxoids: paclitaxel and docetaxel. Cancer Treat Rev 1993; 19: 351–86.
   PubMed Web of Science ®Google Scholar
• Diaz JF, Andreu JM. Assembly of purified GDP-tubulin into microtubules induced by taxol and taxotere. Reversibility, ligand stoichiometry, and competition. Biochemistry 1993; 32: 2747–55.
   Google Scholar
• Schiff PB, Horwitz SB. Taxol stabilized microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA 1980; 77: 1561–5.
   PubMed Web of Science ®Google Scholar
• Tanaka M, Obata T, Sasaki T, et al. Evaluation of antitumor effects of docetaxel (Taxotere) on human gastric cancer in vitro and in vivo. Eur J Cancer 1996; 32A: 226–30.
   PubMed Web of Science ®Google Scholar
• Kim R, Ohi Y, Inoue H, Toge T. Taxotere activates transcrip-tion factor AP-1 in association with apoptotic cell death in gastric cancer cell lines. Anticancer Res 1999; 19: 5399–405.
   PubMedGoogle Scholar
• Sulkes A, Smythe J, Sessa C, et al. Docetaxel (Taxotere) in advanced gastric cancer. Results of a phase II clinical trial. Br J Cancer 1994; 70: 183–4.
   Google Scholar
• Einzig Al, Neuberg D, Remick SC, et al. Phase II trial of docetaxel in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic che-motherapy. The Eastern Cooperative Oncology Group (ECOG) results of protocol E1293. Med Oncol 1996; 13: 87–93.
   Google Scholar
• Giuliani F, Gebbia V, De Vita F, et al. Docetaxel (Taxotere) as a salvage chemotherapy in patients with advanced gastric cancer. A phase II study of the Southern Italian Oncology Group (GOIM). Proc Eur Soc Med Oncol 2000; 25th meeting: 296 abstract.
   Google Scholar
• Mavroudis D, Kourousis C, Androulakis N, et al. Frontline treatment of advanced gastric cancer with docetaxel and granulocyte colony-stimulating factor: a phase II trial. Am J Clin Oncol 2000; 23: 341–4.
   PubMed Web of Science ®Google Scholar
• Vanhoefer U, Wilke H, Harstrick A, et al. Phase II study of docetaxel as second-line chemotherapy in metastatic gastric cancer. Proc Am Soc Clin Oncol 1999; 35th annual meeting: 1163 abstract.
   Google Scholar
• Bang YJ, Kang WK, Kang YK, et al. Docetaxel 75 mg/m(2) is active and well tolerated in patients with metastatic or recurrent gastric cancer: a phase II trial. Jpn J Clin Oncol 2002; 32: 248–54.
   PubMed Web of Science ®Google Scholar
• Taguchi T, Sakata Y, Kanamaru R, et al. Late phase II clinical study of RP56976 (docetaxel) in patients with advanced/ recurrent gastric cancer: a Japanese Cooperative Study Group trial (group A). Gan To Kagaku Ryoho 1998; 25: 1915–24.
   PubMedGoogle Scholar
• Graziano F, Catalino V, Baldelli AM, et al. A phase II study of weekly docetaxel as salvage chemotherapy for advanced gastric cancer. Ann Oncol 2000; 11: 1263–6.
   PubMed Web of Science ®Google Scholar
• Cascinu S, Graziano F, Barni S, et al. A phase II study of sequential chemotherapy with docetaxel after the weekly PELF regimen in advanced gastric cancer. A report from the Italian group for the study of digestive tract cancer. Br J Cancer 2001; 84: 470–4.
   PubMed Web of Science ®Google Scholar
• Hill BT, Whelan RD, Shellard SA, et al. Differential cytotoxic effects of docetaxel in a range of mammalian tumor cell lines and certain drug resistant sublines in vitro. Invest New Drugs 1994; 12: 169–82.
   PubMed Web of Science ®Google Scholar
• Roth AD. Chemotherapy in gastric cancer: a never ending saga. Ann Oncol 2003; 14: 175–7.
   PubMed Web of Science ®Google Scholar
• Mavroudis D, Kourousis C, Androulakis N, et al. Frontline treatment of advanced gastric cancer with docetaxel and granulocyte colony-stimulating factor: a phase II trial. Am J Clin Oncol 2000; 23: 341–4.
   PubMed Web of Science ®Google Scholar
• Burris HA 3rd. Docetaxel in combination with fluorouracil for advanced solid tumors. Oncology (Huntingt) 1997; 11: 50–2.
   PubMedGoogle Scholar
• Constenla M, Lorenzo I, Carrete N, et al. Docetaxel with weekly high-dose 5-FU and lecovorin: a new combination in advanced gastric cancer. Proc Am Soc Clin Oncol 1999; 35th annual meeting: 1079 abstract.
   Google Scholar
• Chun HG, Puccio CA, Mittelman A. Weekly docetaxel and continuous infusion 5-FU in elderly patients with cancer of the stomach and lower esophagus. Proc Am Soc Clin Oncol 2001; 37th annual meeting: 645 abstract.
   Google Scholar
• Enrech S, Belon J, Mendez M, et al. A phase II study of docetaxel in combination with irinotecan (CPT-11) in locally advanced or metastatic gastric cancer. GOTI study group. Proc Am Soc Clin Oncol 2001; 37th annual meeting: 2325 abstract.
   Google Scholar
• Andre T, Louvet C, Ychou M, et al. Docetaxel-epirubicin as second-line treatment for patients with advanced gastric cancer. Proc Am Soc Clin Oncol 1999; 35th annual meeting: 1062 abstract.
   Google Scholar
• Roth AD, Maibach R, Martinelli G, et al. Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO). Ann Oncol 2000 Mar; 11(3): 301–6.
   Google Scholar
• Ridwelski K, Gebauer T, Fahlke J, et al. Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer. Ann Oncol 2001; 12: 47–51.
   PubMed Web of Science ®Google Scholar
• Kettner E, Ridwelski K, Keiholz U, et al. Docetaxel and cisplatin combination chemotherapy for advanced gastric cancer. Results of two phase II studies. Proc Am Soc Clin Oncol 2001; 37th annual meeting: 657 abstract.
   Google Scholar
• Roth AD, Maibach R, Fazio N, et al. 5FU as protracted continuous iv infusion can be added to full dose taxotere-cisplatin in advanced gastric carcinoma. Eur J Cancer 1999; 35(Suppl 4): 139.
   Google Scholar
• Ajani JA, Fodor M, Van Cutsem E, et al. Multinational randomized trial of docetaxel, cisplatin with or without 5-fluorouracil in patients with advanced gastric or GE junction adenocarcinoma. Proc Am Soc Clin Oncol 2000; 36th annual meeting: 957 abstract.
   Google Scholar
• Fuchs CS, Lynch TJ, Earle CC, et al. Phase I trial of Taxotere, cisplatin, and CPT-11 in advanced solid tumor malignancies. ProcAm Soc Clin Oncol 2001; 37th annual meeting: 2087 abstract.
   Google Scholar
• Di Lauro L, Belli F, Del Monte G, Carpano S. Epirubicin, cisplatin, and docetaxel (ECD) for measurable advanced gastric carcinoma. Preliminary data. Proc Eur Soc Med Oncol 2002; 27th meeting: 739 abstract.
   Google Scholar
• Murad AM, Garcia RF, Vinholes J, et al. A phase II multicentric trial of docetaxel (Taxotere), 5-fluorouracil (5-FU) and epirubicin (EPI) in previously untreated advanced gastric cancer: a novel and effective regimen. Proc Eur Soc Med Oncol 2002; 27th meeting: 710 abstract.
   Google Scholar
• Moiseyenko M, Van Cutsem E, Tjulandin S, et al. Docetaxel-cisplatin-5-FU (DCF) versus cisplatin-5-FU (CF) as first line therapy for gastric cancer: interim analysis results on efficacy and safety in a multicenter randomized phase III study. Proc Am Soc Clin Oncol 2002; 38th annual meeting: 587 abstract.
   Google Scholar
• Ostellino O, Porcile G, Alabiso O, et al. TCFW: 5 FU pvi in combination with weekly docetaxel and CDDP in advanced gastric cancer, a phase I-II study: the dose finding step. `Rete Oncologica Piemontese'. Proc Am Soc Clin Oncol 2002; 38th annual meeting: 2234 abstract.
   Google Scholar
• Patience PC, Kretzschmar A, Vielhaber A, et al. Docetaxel and 5-FU continuous infusion (DF) versus epirubicin, cisplatin and 5-FU (ECF) for advanced gastric adenocarcinoma: a rando-mized phase II study. Proc Am Soc Clin Oncol 2002; 38th annual meeting: 647 abstract.
   Google Scholar
• Waters JS, Norman A, Cunningham D, et al. Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. Br J Cancer 1999; 80: 269–72.
   PubMed Web of Science ®Google Scholar
• Findlay M, Cunningham D, Norman A, et al. A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorour-acil (ECF). Ann Oncol 1994; 5: 609–16.
   PubMed Web of Science ®Google Scholar
• Janunger KG, Hafstrom L, Nygren P, Glimelius B. A systema-tic overview of chemotherapy effects in gastric cancer. Acta Oncol 2001; 40: 309–26.
   PubMed Web of Science ®Google Scholar
• Webb A, Cunningham D, Scarffe JH, et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluor-ouracil, doxorubicin, and methotrexate in advanced esophago-gastric cancer. J Clin Oncol 1997; 15: 261–7.
   PubMed Web of Science ®Google Scholar
• Vanhoefer U, Rougier P, Wilke H, et al. Final results of a randomized phase III trial of sequential high-dose methotrex-ate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol 2000; 18: 2648–57.
   PubMed Web of Science ®Google Scholar
• Kelsen D, Atiq OT, Saltz L, et al. FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer. J Clin Oncol 1992; 10: 541–8.
   PubMed Web of Science ®Google Scholar
• Cocconi G, Carlini P, Gamboni A, et al. PELF is more active than FAMTX in Metastatic Gastric Carcinoma (MG. Proc Am Soc Clin Oncol 2001; 37th annual meeting: 501 abstract.
   Google Scholar
• Day RS. Treatment sequencing, asymmetry, and uncertainty: protocol strategies for combination chemotherapy. Cancer Res 1986; 46: 3876–85.
   PubMedGoogle Scholar
• Fizazi K, Zelek L. Is one cycle every three or four weeks' obsolete? A critical review of dose-dense chemotherapy in solid neoplasms. Ann Oncol 2000; 11(2): 133–49.
   PubMed Web of Science ®Google Scholar